How best to forecast the uptake of new pharmaceuticals: Cell and gene therapies

Whether you are forecasting the uptake of a new cell and gene therapy or its impact on existing chronic therapies, there are two major headwinds. First, one-off treatments such as cell and gene therapies eliminate their own treatable patient pool. Second, the uncertainty of a cell and gene therapy’s long-term effectiveness. In this paper, we unveil how to effectively overcome these forecasting challenges and reveal how existing chronic therapies may, in time, get a “second bite of the apple”.

Back to White Papers

Download the document by filling in the form:

By clicking on the “Submit Request” button you are providing consent for us to store your data and contact you. You may withdraw your consent at any time by instructing us at .

View our Privacy Policy for more information.

Please note that Inpharmation literature and case study materials constitute Inpharmation intellectual property and are intended for the pharmaceutical industry. Inpharmation is under no obligation to distribute these materials to non-pharmaceutical industry employees or competitors.

Scroll Top